Viracta Therapeutics completes enrolment for T-cell lymphoma cohort in NAVAL-1 trial
Betsy Goodfellow | March 1, 2024 | News story | Medical Communications | Oncology, Viracta Therapeutics, lymphoma
Viracta Therapeutics has announced that it has completed stage 2 enrolment into the relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) peripheral T-cell lymphoma (PTCL) cohort of its NAVAL-1 trial.
The trial is part of the company’s lead development programme, Nana-val (nanatinostat in combination with valganciclovir), a first in class, oral investigational therapy which targets Epstein-Barr virus (EBV)-associated cancers.
Darrel P Cohen MD PhD, chief medical officer of Viracta Therapeutics, commented: “Given the nature of this serious life-threatening condition and absence of EBV-targeted treatments today, our goal is to bring Nana-val to patients with relapsed or refractory EBV-positive PTCL as quickly as possible. The completion of Stage 2 enrolment of the PTCL cohort in NAVAL-1 is a major milestone for the Nana-val clinical development programme. We would like to acknowledge the dedication of our study execution team and the commitment of our investigators for this achievement. We look forward to building upon our previously published positive data from the phase 1b/2 clinical trial and reporting topline PTCL cohort data from Stage 1 of the NAVAL-1 trial in the second quarter of 2024. Additionally, we plan to meet with FDA in mid-2024 to align on requirements for accelerated approval of Nana-val in this orphan indication.”
Betsy Goodfellow
Related Content
Genmab to submit FDA application for lymphoma therapy
Global biotechnology company Genmab plans to submit a supplemental Biologics License Application (sBLA) to the …
National Institute for Healthcare and Excellence (NICE) recommend BRUKINSA (zanubturinib) for treatment of adult patients with marginal zone lymphoma who have received at least one prior anti-CD20-based therapy.
BeiGene UK announced that BRUKINSA (zanubrutinib) has been recommended by the National Institute for Health …
AstraZeneca shares positive interim results from phase 3 lymphoma trial
AstraZeneca has announced positive high-level results from an interim analysis of the ECHO phase 3 …
